Podcasts about mcl

  • 502PODCASTS
  • 919EPISODES
  • 49mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Sep 23, 2022LATEST

POPULARITY

20152016201720182019202020212022

Categories



Best podcasts about mcl

Show all podcasts related to mcl

Latest podcast episodes about mcl

PanHandles Podcast
Celtics' Coaching Woes, Bojan to Detroit and Jake's Love for the ESPN Top-100

PanHandles Podcast

Play Episode Listen Later Sep 23, 2022 59:51


Derek and Jake cover Boston's latest coaching woes, the Pistons' latest trade, Shai Gilgeous-Alexander's MCL sprain and Jake's deep love for the newest ESPN top-100 list.

Bricktown Breakdown
Bricktown Breakdown: 9/23/22

Bricktown Breakdown

Play Episode Listen Later Sep 23, 2022 36:20


Discussing SGA's MCL sprain and Sam Presti's preseason presser

Podcast
Double Take Sports Talk Podcast Episode 391

Podcast

Play Episode Listen Later Sep 22, 2022 55:19


DTST Podcast 09-21-2022 Sports Talk NFL Fantasy Update News NBA Dennis Schroder, Lakers agree to one year- $2.64 million deal Lonzo Ball will undergo arthroscopic surgery on left knee Shai Gilgeous-Alexander suffers MCL sprain, to miss start of training camp Platform Talk Afternoon Coffee Break Robert Sarver Breaking Mental Health Do your best Open Conversation/What's Next Open Conversation Darren - The struggle is real Darrell - Gary Vee What's Next? Platform Talk Fantasy Update News and Headlines **EEOC website: https://www.eeoc.gov/youth/what-employment-discrimination --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/double-take-sports-talk/support

Fantasy Football Podcast
MUST ADD NFL Week 3 Fantasy Football Waiver Wire Pickups | Jimmy Garoppolo + Marcus Mariota + more

Fantasy Football Podcast

Play Episode Listen Later Sep 20, 2022 54:01


MUST ADD NFL Week 3 Fantasy Football Waiver Wire Pickups | Jimmy Garoppolo + Marcus Mariota + moreRight now on the FF Faceoff, Anthony Cervino (@therealnflguru) and Frank Ammirante are here to break down their top Fantasy Football Waiver Wire Must Add Players for NFL Week 3. The latest NFL News, Rumors, and Injuries will also be discussed as will live listener Q and A. *BE HEARD -- Ask your questions in the LIVE CHATTalking Points:Don't overreact: 03:50Kyle Pitts: 06:00Elijah Moore: 09:00Joe Burrow: 11:45Kyle Pitts: 13:50Austin Ekeler: JuJu: 21:00CeeDee Lamb: 18:30Jimmy Garoppolo: 23:00Evan Engram and Zay Jones: 24:50Raheem Mostert: 32:15Garrett Wilson: 34:40Russell Gage:37:30Marcus Mariota43:00 Daniel Jones, Jameis Winston, Joe Flacco: 46:40Gerald Everett: 52:00Get a 100% deposit bonus of up to $25 when you use the promo code FACEOFF at sign upSign Up Here: https://bit.ly/Faceoff-NHANFL News: 49ers TE Tyler Kroft (knee) has been diagnosed with a sprained MCL and will be sidelined for a "few weeks" | 49ers RB Tyrion Davis-Price has been diagnosed with a high-ankle sprain and will be sidelined for a "few weeks" | Browns listed RT Jack Conklin (knee) as a limited participant on their Monday practice report | Cowboys HC Mike McCarthy said the team won't know about Dalton Schultz's (knee) Week 3 status until game time | Colts HC Frank Reich said Michael Pittman (quad) "made good progress" in his recovery and could play in Week 3 Want Free Money?Sportbooks Affiliates:1. Fubo - Risk-Free Bet up to $1000Link: https://www.bestodds.com/visit/fubo-faceoff/2. BetMGM - Risk-Free Bet up to $1000Link: https://www.bestodds.com/visit/betmgm-faceoff/3. Caesars - Risk-Free Bet up top $1100Link: https://www.bestodds.com/visit/caesars-faceoff/4. PointsBet - 2 Risk-Free Bets up to $2000Link: https://www.bestodds.com/visit/pointsbet-faceoff/DFS Affiliates:1. Prize Picks (Promo Code FACEOFF)Get a 100% Deposit Match up to $100Join Here: https://app.prizepicks.com/sign-up?invite_code=FACEOFF2. Underdog Fantasy (Promo Code: FACEOFF) All NEW USERS get a first deposit matchup up to $100Link to join: https://play.underdogfantasy.com/p-ff-faceoffWEBSITE: www.fffaceoff.comDISCORD: https://discord.gg/hEYgqxcvYjLINKTREE: https://linktr.ee/fffaceoffMERCH: https://veridianglobal.com/collections/ff-faceoff--------------------------------------------------------HOUSE-KEEPING---------------------------------------------------------------EMAIL: ffaceoff@gmail.com TWITTER:https://twitter.com/fffaceoffhttps://twitter.com/therealnflguruIG: https://www.instagram.com/thefffaceoffFACEBOOK: https://www.facebook.com/FFFaceoff/FACEBOOK GROUP: https://www.facebook.com/groups/2213414128877661/?ref=pages_profile_groups_tab&source_id=918684538289626SUBSCRIBE to dominate your competition https://www.youtube.com/thefffaceoff?sub_confirmation=1APPLE POD: https://itunes.apple.com/us/podcast/the-ff-faceoff/id1340277737?mt=2GOOGLE POD: https://playmusic.app.goo.gl/?ibi=com.google.PlayMusic&isi=691797987&ius=googleplaymusic&apn=com.google.android.music&link=https://play.google.com/music/m/Ioht3362q3s5ov4bqj4nigpf2xi?t%3DThe_FF_Faceoff%26pcampaignid%3DMKT-na-all-co-pr-mu-pod-16

Fantasy Football Podcast
Week 2 Fantasy Football REACTION + Recap + Trey Lance + Tyreek Hill + Lamar Jackson + more

Fantasy Football Podcast

Play Episode Listen Later Sep 20, 2022 64:50


Week 2 Fantasy Football REACTION + Recap + Trey Lance + Tyreek Hill + Lamar Jackson + moreNow on the FF Faceoff, Anthony Cervino, Matt MacKay (@Matt_MacKay_), and Steve DeAngelo (@fantasysavvy) are back to break down the NFL Week 1 slate in the Fantasy Football Week 2 Reactions show including winners, losers, studs, duds, NFL News and more.*BE HEARD -- Ask your questions in the LIVE CHATTalking Points:Trey Lance: 05:00Saquon Barkley for Ekeler Dynasty: 15:30Justin Jefferson trade value: 18:00Garrett Wilson, London, Olave?: 20:00Tua: 25:30Joe Burrow: 36:30Tony Pollard: 38: 00Amon-Ra St. Brown: 47:00Justin Fields: 56:00Get a 100% deposit bonus of up to $25 when you use the promo code FACEOFF at sign upSign Up Here: https://bit.ly/Faceoff-NHANFL News: 49ers TE Tyler Kroft (knee) has been diagnosed with a sprained MCL and will be sidelined for a "few weeks" | 49ers RB Tyrion Davis-Price has been diagnosed with a high-ankle sprain and will be sidelined for a "few weeks" | Browns listed RT Jack Conklin (knee) as a limited participant on their Monday practice report | Cowboys HC Mike McCarthy said the team won't know about Dalton Schultz's (knee) Week 3 status until game time | Colts HC Frank Reich said Michael Pittman (quad) "made good progress" in his recovery and could play in Week 3 against the ChiefsWant Free Money?Sportbooks Affiliates:1. Fubo - Risk-Free Bet up to $1000Link: https://www.bestodds.com/visit/fubo-faceoff/2. BetMGM - Risk-Free Bet up to $1000Link: https://www.bestodds.com/visit/betmgm-faceoff/3. Caesars - Risk-Free Bet up top $1100Link: https://www.bestodds.com/visit/caesars-faceoff/4. PointsBet - 2 Risk-Free Bets up to $2000Link: https://www.bestodds.com/visit/pointsbet-faceoff/DFS Affiliates:1. Prize Picks (Promo Code FACEOFF)Get a 100% Deposit Match up to $100Join Here: https://app.prizepicks.com/sign-up?invite_code=FACEOFF2. Underdog Fantasy (Promo Code: FACEOFF) All NEW USERS get a first deposit matchup up to $100Link to join: https://play.underdogfantasy.com/p-ff-faceoffWEBSITE: www.fffaceoff.comDISCORD: https://discord.gg/hEYgqxcvYjLINKTREE: https://linktr.ee/fffaceoffMERCH: https://veridianglobal.com/collections/ff-faceoff--------------------------------------------------------HOUSE-KEEPING---------------------------------------------------------------EMAIL: ffaceoff@gmail.com TWITTER:https://twitter.com/fffaceoffhttps://twitter.com/therealnflguruIG: https://www.instagram.com/thefffaceoffFACEBOOK: https://www.facebook.com/FFFaceoff/FACEBOOK GROUP: https://www.facebook.com/groups/2213414128877661/?ref=pages_profile_groups_tab&source_id=918684538289626SUBSCRIBE to dominate your competition https://www.youtube.com/thefffaceoff?sub_confirmation=1APPLE POD: https://itunes.apple.com/us/podcast/the-ff-faceoff/id1340277737?mt=2GOOGLE POD: https://playmusic.app.goo.gl/?ibi=com.google.PlayMusic&isi=691797987&ius=googleplaymusic&apn=com.google.android.music&link=https://play.google.com/music/m/Ioht3362q3s5ov4bqj4nigpf2xi?t%3DThe_FF_Faceoff%26pcampaignid%3DMKT-na-all-co-pr-mu-pod-16

Answers from the Lab
Leading diagnostics into the future: Dr. Bill Morice

Answers from the Lab

Play Episode Listen Later Sep 19, 2022 13:17


William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, they discuss Dr. Morice's new role as CEO and president of Mayo Clinic Laboratories (MCL), his patient-centered vision for the future, and how MCL is leading positive changes in the diagnostics industry.

Willard & Dibs
Dr. Nirav Pandya joins Willard and JD

Willard & Dibs

Play Episode Listen Later Sep 14, 2022 6:00


Associate Professor of UCSF Orthopedic Surgery Dr. Nirav Pandya joins the program to discuss the latest on Elijah Mitchell's MCL injury, George Kittle's groin, and more. 

Locked On Today
The Dallas Cowboys have a bleak NFL regular season ahead of them

Locked On Today

Play Episode Listen Later Sep 13, 2022 24:47


Without Dad Prescott, the Dallas Cowboys are listless this year. The Pittsburgh Steelers may be without two key players for awhile. Baker Mayfield and the Carolina Panthers were robbed on Sunday. Also, San Francisco 49ers running back Elijah Mitchell will miss significant time with a sprained MCL, New York Jets coach Robert Sales is keeping receipts from Jets doubters, Texas A&M coach Jimbo Fisher is evaluating everything after loss to Appalachian State, Utah Jazz president of basketball ops Danny Ainge was concerned with the Jazz' culture, and the Seattle Seahawks did to Russell Wilson and the Denver Broncos what the Seahawks used to do with Wilson and that's win at home. Linktree.com/LockedOnNBA Linktree.com/LockedOnNFL Linktree.com/LockedOnMLB Linktree.com/LockedOnNHL  Support Us By Supporting Our Sponsors! Built Bar Built Bar is a protein bar that tastes like a candy bar. Go to builtbar.com and use promo code “LOCKEDON15,” and you'll get 15% off your next order. BetOnline BetOnline.net has you covered this season with more props, odds and lines than ever before. BetOnline – Where The Game Starts! Learn more about your ad choices. Visit podcastchoices.com/adchoices

49ers Cutback
49ers News Update - Elijah Mitchell Out | George Kittle Close? | Sign Marlon Mack or Tevin Coleman

49ers Cutback

Play Episode Listen Later Sep 13, 2022 15:19


Elijah Mitchell has a sprained MCL and is out 8 to 10 weeks. Who will the 49ers use to replace him? Will they sign a free agent? Also Kittle almost played on Sunday, Is he close to playing against Seattle? --- Support this podcast: https://anchor.fm/49ers-cutback/support

Chop Sports Daily
NFL Week 1 Reactions & Overreactions | September 12th, 2022

Chop Sports Daily

Play Episode Listen Later Sep 12, 2022 76:53


Welcome back to Chop Sports Daily! The NFL is in full effect now and Chris and Dave react to all of the games played on Sunday, Saquon Barkley helped the Giants win, Dak Prescott out for 6-8 weeks, Elijah Mitchell is out for two months with a MCL sprain and closing out the show the guys do a deep dive into the rest of the games on Sunday and preview Monday Night's matchup between the Denver Broncos and Seattle Seahawks.

Positively RELENTLESS
Exploring the greatest "what if" in Dallas Mavs history | Positively Relentless #17

Positively RELENTLESS

Play Episode Listen Later Sep 8, 2022 75:10


The 2002-2003 Dallas Mavericks are one of the single greatest "what if's" in modern NBA history. If not for a sprained MCL in Game 3 for Dirk Nowitzki, Dallas likely slays the eventual champions and then makes quick work of the New Jersey Nets in the Finals to claim their first title. A championship for the Filthy, Dirty, Nasty Mavs means Steve likely never leaves for Phoenix, and his MVP-caliber basketball is lived out in Dallas. It also means the now second-winningest coach in NBA history, Don Nelson, gets himself a title and redefines his legacy. Who knows what would've followed had this great "what if" gone just a little differently. Let's throwdown! --- Support this podcast: https://anchor.fm/dallas-prospect/support

Zalma on Insurance
Surveillance Establishes Fraud Defense

Zalma on Insurance

Play Episode Listen Later Sep 5, 2022 10:11


Michigan Allows Fraudster to Receive PIP Benefits but no UM/UIM Benefits Plaintiff appealed the trial court's order granting summary disposition in favor of defendants Home-Owners Insurance Company (“Home-Owners”), American Country Insurance Company (ACIC), and Hartford Accident and Indemnity Company (“Hartford”), with respect to plaintiff's claims for uninsured or underinsured motorist benefits and first-party personal protection insurance (PIP) benefits under the no-fault act, MCL 500.3101 et seq. Although defendants disputed their priority to pay PIP benefits, the trial court did not decide the priority issue, but instead dismissed all claims on the basis of antifraud provisions in defendants' respective policies --- Support this podcast: https://anchor.fm/barry-zalma/support

Aging-US
Press Release: Synergism Of BCL-2 Inhibitors Facilitates Selective Elimination Of Senescent Cells

Aging-US

Play Episode Listen Later Sep 2, 2022 4:38


A new research paper was published in Aging (“Aging (Albany NY)” by Medline/PubMed, “Aging-US” by Web of Science) on the cover of Volume 14, Issue 16, entitled, “Synergism of BCL-2 family inhibitors facilitates selective elimination of senescent cells.” Cellular senescence, a complex cellular response to stress characterized by a halt of cell cycle progression, is one factor contributing to aging. Accumulation of senescent cells in tissues with advancing age participates in the pathogenesis of several human age-associated diseases. Specific senescent secretome, the resistance of senescent cells to apoptotic stimuli, and lack of immune system response contribute to the accumulation of senescent cells and their adverse effects in tissues. Inhibition of antiapoptotic machinery, augmented in senescent cells, by BCL-2 protein family inhibitors represents a promising approach to eliminate senescent cells from tissues. “In this study, with the goal of decreasing the toxicity and potential onset of resistance to senolytic BCL-2 inhibitor monotherapy, we explored the effects of combined treatment covering both BCL-2 and MCL-1 anti-apoptotic factors in human cells.” Researchers David Rysanek, Pavla Vasicova, Jayaprakash Narayana Kolla, David Sedlak, Ladislav Andera, Jiri Bartek, and Zdenek Hodny from the Czech Academy of Sciences and the Danish Cancer Society Research Center aimed to explore synergistic and selective senolytic effects of anti-apoptotic BCL-2 family targeting compounds, particularly BH3 mimetics. “Using human non-transformed cells RPE-1, BJ, and MRC-5 brought to ionizing radiation-, oncogene-, drug-induced and replicative senescence, we found synergy in combining MCL-1 selective inhibitors with other BH3 mimetics.” In an attempt to uncover the mechanism of such synergy, the team revealed that the surviving subpopulation of cells resistant to individually applied ABT-737/ABT-263, MIK665, ABT-199, and S63845 BCL-2 family inhibitors showed elevated MCL-1 compared to untreated control cells indicating the presence of a subset of cells expressing high MCL-1 levels and, therefore, resistant to BCL-2 inhibitors within the original population of senescent cells. Overall, the researchers found that combining BCL-2 inhibitors can be beneficial for eliminating senescent cells, thereby enabling use of lower, potentially less toxic, doses of drugs compared to monotherapy, thereby overcoming the resistance of the subpopulation of senescent cells to monotherapy. DOI: https://doi.org/10.18632/aging.204207 Corresponding Author: Jiri Bartek, Zdenek Hodny – Email: jb@cancer.dk, hodny@img.cas.cz Keywords: homoharringtonine, cellular senescence, BCL-2, MCL-1, senolytics Sign up for free Altmetric alerts about this article: https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204207 About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus​ LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/

MMA Fighting
‘DAMN! That Was Crazy' | Looking Back At UFC 151's Cancellation with the 'Sport Killer'

MMA Fighting

Play Episode Listen Later Sep 1, 2022 111:11


While DAMN! They Were Good normally celebrates the careers of the most exciting and influential fighters in MMA history, for the 10-year anniversary of one of the biggest fiascos in UFC history, this week DAMN! will dive deep into the first fight card the UFC ever cancelled, UFC 151. UFC 151 was set to be headlined by a light heavyweight title fight between Jon Jones and Dan Henderson, but eight days before the event, Henderson informed the UFC he ruptured his MCL and would be unable to compete. The promotion scrambled to find a replacement and settled on Chael Sonnen, but Jones and his team refused the short notice fight. In the end, the UFC cancelled the event and laid the blame square upon Jones and his coach Greg Jackson, releasing a scathing press release and adding the term "Sport Killer" to the MMA lexicon. Follow Jed Meshew @JedKMeshew Follow Shaun Al-Shatti @ShaunAlShatti Follow Alexander K. Lee @AlexanderKLee Subscribe: http://goo.gl/dYpsgH Check out our full video catalog: http://goo.gl/u8VvLi Visit our playlists: http://goo.gl/eFhsvM Like MMAF on Facebook: http://goo.gl/uhdg7Z Follow on Twitter: http://goo.gl/nOATUI Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

MMA Fighting
‘DAMN! That Was Crazy' | Looking Back At UFC 151's Cancellation with the 'Sport Killer'

MMA Fighting

Play Episode Listen Later Sep 1, 2022 111:11


While DAMN! They Were Good normally celebrates the careers of the most exciting and influential fighters in MMA history, for the 10-year anniversary of one of the biggest fiascos in UFC history, this week DAMN! will dive deep into the first fight card the UFC ever cancelled, UFC 151. UFC 151 was set to be headlined by a light heavyweight title fight between Jon Jones and Dan Henderson, but eight days before the event, Henderson informed the UFC he ruptured his MCL and would be unable to compete. The promotion scrambled to find a replacement and settled on Chael Sonnen, but Jones and his team refused the short notice fight. In the end, the UFC cancelled the event and laid the blame square upon Jones and his coach Greg Jackson, releasing a scathing press release and adding the term "Sport Killer" to the MMA lexicon. Follow Jed Meshew @JedKMeshew Follow Shaun Al-Shatti @ShaunAlShatti Follow Alexander K. Lee @AlexanderKLee Subscribe: http://goo.gl/dYpsgH Check out our full video catalog: http://goo.gl/u8VvLi Visit our playlists: http://goo.gl/eFhsvM Like MMAF on Facebook: http://goo.gl/uhdg7Z Follow on Twitter: http://goo.gl/nOATUI Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

MMA Fighting
‘DAMN! That Was Crazy' | Looking Back At UFC 151's Cancellation with the 'Sport Killer'

MMA Fighting

Play Episode Listen Later Sep 1, 2022 111:11


While DAMN! They Were Good normally celebrates the careers of the most exciting and influential fighters in MMA history, for the 10-year anniversary of one of the biggest fiascos in UFC history, this week DAMN! will dive deep into the first fight card the UFC ever cancelled, UFC 151. UFC 151 was set to be headlined by a light heavyweight title fight between Jon Jones and Dan Henderson, but eight days before the event, Henderson informed the UFC he ruptured his MCL and would be unable to compete. The promotion scrambled to find a replacement and settled on Chael Sonnen, but Jones and his team refused the short notice fight. In the end, the UFC cancelled the event and laid the blame square upon Jones and his coach Greg Jackson, releasing a scathing press release and adding the term "Sport Killer" to the MMA lexicon. Follow Jed Meshew @JedKMeshew Follow Shaun Al-Shatti @ShaunAlShatti Follow Alexander K. Lee @AlexanderKLee Subscribe: http://goo.gl/dYpsgH Check out our full video catalog: http://goo.gl/u8VvLi Visit our playlists: http://goo.gl/eFhsvM Like MMAF on Facebook: http://goo.gl/uhdg7Z Follow on Twitter: http://goo.gl/nOATUI Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Boss and the Brewer
BatB #46 – Is Good Better than Mighty

The Boss and the Brewer

Play Episode Listen Later Aug 31, 2022 105:02


Mighty Craft Results - https://theshout.com.au/another-year-of-record-sales-growth-for-mighty-craft/$63m revenue - $6.3m loss (10%) (adjusted for a lot of things, actual $11.6m almost 20%)“FY22 saw Torquay Beverage Company launch Better Beer with the Inspired Unemployed, which delivered $19m of sales and sold 4.3m litres since its launch in October 2021.”“As mentioned, we have engaged Moelis Australian to facilitate a review of the company's strategic options. We have two emerging segments in the business and both these businesses require different levels of investment over different timeframes. We are firmly of the view that the current market capitalisation doesn't reflect the intrinsic value of the brands, and believe the time is right to commission the strategic review.”Link to presentation - https://wcsecure.weblink.com.au/pdf/MCL/02561809.pdf Adelaide Hills revenue $18.2m, Profit $3.4m (They paid $47m, forecast FY22 profit of $6m) - Mighty Craft's entire market cap is $49m. Share price in June 2021 37c, now 15c - market cap $121m Behemoth NZ Crowdfunding - https://www.snowballeffect.co.nz/offers/preview/behemoth-8wsc7 370 people opted in$3m goal$11m revenueRaised last year Raised July 2019 $1.8m (or $2m? Confusing - 627 investors - https://www.pledgeme.co.nz/investments/360-behemoth-brewing Projection in 2019 - 2022 Revenue $12.5m, Profit $2.25m Projection in 2021 - 2022 Revenue $13.4m Profit $2.6m 5% Dividends by FY24XXXX to upgrade for Seltzer - https://www.brewsnews.com.au/2022/08/29/5m-xxxx-seltzer-investment/ Coles results - more own brand and more local https://www.brewsnews.com.au/2022/08/26/coles-liquor-focuses-on-local-as-sales-grow/ Eagle Bay Beer Recalled By Woolies / Coles Recall - https://www.perthnow.com.au/news/woolworths-coles-recall-popular-eagle-bay-brewing-company-beer-c-8025186 BOC invests in Co2 facility - https://www.brewsnews.com.au/2022/08/31/boc-invests-in-co2-facility/ 12 questions

CCO Oncology Podcast
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022

CCO Oncology Podcast

Play Episode Listen Later Aug 30, 2022 28:34


In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLLBRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor)BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator's choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCLBRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCLPresenters: Julie M. Vose, MD, MBAChief, Division of Oncology and HematologyNeumann M. and Mildred E. Harris ProfessorDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaMatthew S. Davids, MD, MMScAssociate Professor of MedicineHarvard Medical SchoolDirector of Clinical ResearchDivision of LymphomaDana-Farber Cancer InstituteBoston, MassachusettsLink to full program:https://bit.ly/3OQ6634

CommonsCast
Episode 106: CommonsCast Episode 106-August 31, 2022

CommonsCast

Play Episode Listen Later Aug 30, 2022 17:20


On this episode of the podcast MCL's own Linda hosts Q&A with Dean Gresalfi, Santana delivers the details on events coming up this week in the Commons Calendar, and Daniela sits down with Abigail Kwon, a first-year student from Los Angeles who lives in Gillette and plans on majoring in Secondary Education.

Zalma on Insurance
Surveillance Establishes Fraud Defense

Zalma on Insurance

Play Episode Listen Later Aug 29, 2022 14:34


Michigan Allows Fraudster to Receive PIP Benefits but no UM/UIM Benefits Plaintiff appealed the trial court's order granting summary disposition in favor of defendants Home-Owners Insurance Company (“Home-Owners”), American Country Insurance Company (ACIC), and Hartford Accident and Indemnity Company (“Hartford”), with respect to plaintiff's claims for uninsured or underinsured motorist benefits and first-party personal protection insurance (PIP) benefits under the no-fault act, MCL 500.3101 et seq. Although defendants disputed their priority to pay PIP benefits, the trial court did not decide the priority issue, but instead dismissed all claims on the basis of antifraud provisions in defendants' respective policies. In Jonathan Jones v. Home-Owners Insurance Company, American Country Insurance Company, And Hartford Accident & Indemnity Company, and Sharneta Henderson, No. 355118, Court of Appeals of Michigan (August 18, 2022) the Court of Appeal produced a Solomon-like decision. BASIC FACTS This case arises from a motor vehicle accident on October 28, 2017, in which plaintiff's vehicle was struck by a vehicle driven by defendant Sharneta Henderson in Detroit. Plaintiff alleges that he was operating a 2009 Ford Crown Victoria and was stopped at a red light when Henderson's vehicle, traveling at a high rate of speed, drove through a red light and struck his vehicle. Plaintiff sued all three insurers for recovery of no-fault PIP benefits and also uninsured or underinsured motorist benefits. All three insurers filed motions for summary disposition, asserting that plaintiff's claims were barred by antifraud provisions in the respective policies. SUMMARY DISPOSITION PRIORITY UNDER MCL 500.3114 Initially, the Court of Appeal concluded that the trial court erred by failing to address which insurer had priority to pay PIP benefits under MCL 500.3114. The general rule is that one looks to a person's own insurer for no-fault benefits unless one of the statutory exceptions applies. An individual may be entitled to PIP benefits mandated by the no-fault act even if the person is not a named insured “under a no-fault policy, and such a person is not subject to the policy's antifraud provision.” Because the plaintiff's entitlement to no-fault benefits was governed by statute, the exclusionary provision in the defendant's no-fault policy did not apply and could not operate to bar the plaintiff's claims. POST-PROCUREMENT FRAUD --- Support this podcast: https://anchor.fm/barry-zalma/support

Sports Medicine on Tap
Episode 57 - Kayvon Thibodeaux, MCL Injuries

Sports Medicine on Tap

Play Episode Listen Later Aug 26, 2022 34:10


Brandon and Steve talk about why, if you have injured your knee, MCL injury is probably what you are hoping for. We talk about Kayvon Thibodeaux, the 1st pick of the Giants, and many others. We also talk about why sometimes this injury can be far worse....

It's a Football Podcast!
Unmasking NFL rosters: Will Tampa Bay suffer from Tom Brady's absence?

It's a Football Podcast!

Play Episode Listen Later Aug 25, 2022 50:33


Tom Brady made his return to the Tampa Bay Buccaneers. The seven-time champion denied spending time filming FOX TV competition the Masked Singer but didn't share much more. In addition to questions about his absence, UFC president Dana White created quite the buzz saying he almost facilitated the quarterback and tight end Rob Gronkowski's move to the Las Vegas Raiders. And current Raiders QB Derek Carr took it all in stride.  Baker Mayfield gets the starting job with the Carolina Panthers. In Seattle, meanwhile, coach Pete Carroll hasn't yet committed to QB Drew Lock. One thing that is a sure thing is betting on the Baltimore Ravens in preseason, who won their 22nd preseason game. Someone not as lucky, New York Giants rookie Kayvon Thibodeaux sprained his MCL after a hit that caused heated debate across the league.  In other news, Cincinnati Bengals safety Jessie Bates finally signed a franchise tag with the team, Los Angeles Chargers cornerback J.C. Jackson will miss a few weeks with injury and Washington Commanders defensive end Chase Young moved to the reserve/PUP list. Plus, the NFL insiders on players coaching players and the Manti Te'o documentary.  Welcome to It's a Football Podcast! with USA TODAY Sports+ Insiders Safid Deen and Tyler Dragon. Each week the insiders take you to the field and behind the scenes covering every X and O because they know football. But, what's it called?

Buccaneers Observer
[295] Tennessee Titans game reaction, Injuries, Roster moves, and Brady's absence

Buccaneers Observer

Play Episode Listen Later Aug 24, 2022 73:17


The Buccaneers performance against the Tennessee Titans in the second preseason game left something to desired. In contrast to the first game where the receivers and tight ends really shone, there was no player or position group that stood out in the second week. We saw some notable starters in this game, including Leonard Fournette, S Mike Edwards and second string CB Jamel Dean. We lost a potential starter in G Aaron Stinnie when he suffered an ACL tear and MCL sprain in the third quarter. Stinnie went on IR and is lost for the season. Rookie guard Luke Goedeke is getting first string snaps at guard in the aftermath of the injury. T Tristan Wirfs strained an oblique last week at practice with the Titans but should be ready by the regular season. After much fanfare and conjecture, Tom Brady returned to practice this week from his 11-day hiatus. A theory emerged last week that Brady may be a contestant on the Masked Singer. NFL insiders insist the absence was for a family vacation scheduled during Brady's brief retirement. We may see some starters in the upcoming matchup against the Indianapolis Colts. --- Send in a voice message: https://anchor.fm/buccaneers-observer/message Support this podcast: https://anchor.fm/buccaneers-observer/support

Oncotarget
Epigenetics and Immunotherapy Combined Fights Rare Lymphoma

Oncotarget

Play Episode Listen Later Aug 24, 2022 7:11


Listen to a blog summary of a recent research paper published by Oncotarget, entitled, "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma." __________________________________________ Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL) that is aggressive, difficult to treat and typically affects older adults. Recurrence and mortality rates among patients with MCL have remained high, despite recent therapeutic advances. Blastic mantle cell lymphoma (bMCL) is a rare subtype of MCL associated with a worse disease trajectory. “Despite recent advances, MCL is incurable except with allogeneic stem cell transplant. Blastic mantle cell lymphoma (bMCL) is a rarer subtype of cMCL associated with an aggressive clinical course and poor treatment response, frequent relapse and poor outcomes.” In previous studies, researchers reported that a combination of epigenetic and immunotherapy treatments may have synergistic activity and offer better outcomes in patients with MCL. In the current study, Francis R. LeBlanc, Zainul S. Hasanali, August Stuart, Sara Shimko, Kamal Sharma, Violetta V. Leshchenko, Samir Parekh, Haiqing Fu, Ya Zhang, Melvenia M. Martin, Mark Kester, Todd Fox, Jiangang Liao, Thomas P. Loughran, Juanita Evans, Jeffrey J. Pu, Stephen E. Spurgeon, Mirit I. Aladjem, and Elliot M. Epner from Pennsylvania State University College of Medicine, Penn State Hershey Cancer Institute, Winter Haven Hospital Cassidy Cancer Center, Icahn School of Medicine at Mount Sinai, National Cancer Institute, University of Virginia, UVA Cancer Center, University of Arizona College of Medicine, Oregon Health and Science University, and Beverly Hills Cancer Center used samples from a previous trial to perform correlative studies focused on clinical results in patients with blastic MCL. On August 16, 2022, their research paper was published in Volume 13 of Oncotarget, entitled, “Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.” Full blog - https://www.oncotarget.org/2022/08/24/epigenetics-and-immunotherapy-combined-fights-rare-lymphoma/ DOI - https://www.oncotarget.com/article/28258/text/ Correspondence to - Francis R. LeBlanc - francis.leblanc@cchmc.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28258 Keywords - epigenetics, blastic mantle cell lymphoma, cladribine About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Bleav in Giants
Pre-Season Game 2 Recap and Thibodeaux Injury News

Bleav in Giants

Play Episode Listen Later Aug 22, 2022 35:42


Papa & Banks are back to talk Kayvon Thibodeaux's MCL sprain on the gruesome cut block in this past weekend's pre-season game against the Bengals. Carl gives his thoughts on whether the play was dirty or clean and which of his contemporaries in the media got it right. They touch on Daboll's thoughts in the presser on injuries in the pre-season across the NFL, situational football, and Carl gives an offensive lineman pick to surprise all the Giants fans out there. More coming next week and as always #TellAFriendToTellAFriend

Touchdowns and Tangents

#LetsTalkAboutItDeshaun Watson suspended 11 games with a $5 million fineDerwin James get record contract extension for safeties with 4-year $76.4M extension. $42 million guaranteed. Joe Burrow ruptured his appendix#CollegeFootballNewsBig 10 inks agreement to distribution agreements with CBS, Fox, NBC and NBCUniversal's Peacock, as well as returning partners Big Ten Network and FS1, that will begin July 1, 2023, and run through the 2029-30 seasonNew college football rules: https://syndication.bleacherreport.com/amp/10045846-ncaa-tweaks-rules-for-targeting-fake-injuries-ahead-of-2022-cfb-season.amp.htmlLike Knox, 22, FIU linebacker and younger brother of Bills tight end Dawson Knox found dead.#TakeOrTangentEA and the NFL have announced a multi-year renewal of their partnership that guarantees the continuation of their Esports league, the Madden NFL Championship Series (MCS).Zach Wilson injures MCL, Joe Flacco to start vs RavensDeion Sanders says Hall of Fame is watered down#TouchdownOrTurnoverTraining camp/preseason fightsKurt Cousins clarifies “If I Die I Die” comments in wake of getting Covid-19 againLamar Jackson shutting down contract talks during the season. #UnnecessaryToughnessRants

Answers from the Lab
PMND1: John Lieske, M.D.

Answers from the Lab

Play Episode Listen Later Aug 16, 2022 8:26


(00:31)  Could you tell us a bit about yourself and your background?(01:11) Could you describe these new tests and when it would be appropriate to use each of them in the clinic?(03:16) Could you provide a little background on why MCL is making changes to the PLA2R test?(04:34) Could you describe the change to KDIGO guidelines and when it may be appropriate to skip the biopsy? How will these new tests help physicians implement these new guidelines in their practices?

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

The Quidditas Factor
Believing In Yourself, and The Rest Will Fall Into Place with Mark Christopher Lawrence

The Quidditas Factor

Play Episode Listen Later Aug 9, 2022 42:05


Mark Christopher Lawrence is best known for his series regular role as Big Mike on the NBC TV series CHUCK. He recently completed production on the hit ADULT SWIM TV show BLACK JESUS and is recurring on The PureFlix Show Malibu Dan The Family Man. He can be seen on the Disney Channel's original TV movie Life Is Ruff and guest appearances on Lab Rats, Good Luck Charlie, Heroes, Weeds, My Name Is Earl, Reba, Grounded for Life, Crossing Jordan, and Amazing America with Sarah Palin. MCL is in pre-production on several projects as a writer and/or producer and has just released on PureFlix.com his hilarious talk show Pure Comedy, which he also hosts. On video, you can watch MCL's work in The Pursuit of Happyness, The Island, Garfield, Terminator II, Fear of a Black Hat, and Cooties to list a few.As a producer Mark Christopher Lawrence has produced a six episode series for PureFlix  entitled Pure Comedy. He co-produced the first VR comedy special, Mark Christopher Lawrence Live from the Mad House Comedy Club. This work has received the DreamlandXR award for Best Director and has been a FireFox VR Pick of the Week as well as having been nominated for an Emmy award. He's currently in pre-production on his one-man stage show and an album of hymns where he showcases his more than capable vocal prowess. Support the show

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

No Name MMA Show
#102- Our most mid episode yet.

No Name MMA Show

Play Episode Listen Later Aug 3, 2022 25:25


Andy is by himself this weekend discussing First off it looks like Dustin Porier vs Michael chandler is gfetting set up for ufc 281 in november, yeah that the MSG card Speaking of lightweight we conor Mcgergorfollowing in the steps of Kamaru Usman by making his film debut, he will be starring alongside Jake Gylanhall in the remake of Road House Attempts to turn the film into a franchise, however, have been far less successful. A direct to video sequel back in 2006 has found a home in Goodwill bargain bins everywhere, and a 2015 announcement of a remake starring former UFC star Ronda Rousey gratefully died in pre-production. And another battle of the simps has been announced with Tracy Cortez set to take on Amanda Ribas for the card in december Anthony Smith headed for surgery after UFC 277 ankle break Former UFC title contender Anthony Smith is headed for surgery after he broke his ankle at UFC 277. Tom Aspinall reveals torn MCL and meniscus in UFC London loss to Curtis Blaydes, set for surgery Colby Covington finishes seventh in massive poker tournament, cashes for nearly $50,000 Yair rodriguez stated over the weekend that he is going to wait for Alexander Volkanovski to come back for a shot at a title, will not fight Emett for interim, doesnt care if Volk goes to fight at lightweight first --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/nonamemmashow/support

Locked On Cardinals - Daily Podcast On The St. Louis Cardinals Podcast
Does the Steven Matz Injury Change The Juan Soto Plans?

Locked On Cardinals - Daily Podcast On The St. Louis Cardinals Podcast

Play Episode Listen Later Jul 25, 2022 33:08 Very Popular


Not only did the St, Louis Cardinals lost two of three games over the weekend, but they also lost Steven Matz to injury (again). Matz was cruising against the Reds on Saturday before tearing his MCL in an attempt to field a ground ball. It was never a secret that the Cardinals need pitching, but does this loss steer them in a direction away from Juan Soto and towards picking up a few arms at the deadline? Also, with no Paul Goldschmidt or Nolan Arenado in Toronto, who needs to step up for the Cardinal offense? WANT MORE DAILY ST. LOUIS CARDINALS CONTENT? Follow & Subscribe to the Podcast on these platforms…

CCO Oncology Podcast
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

CCO Oncology Podcast

Play Episode Listen Later Jul 21, 2022 26:22


In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLLFLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy durationBRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCLPresenters:Othman Al-Sawaf, MDFaculty of MedicineUniversity Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, GermanyVisiting ScientistThe Francis Crick InstituteUCL Cancer Institute, University College London London, United KingdomLydia Scarfò, MDLaboratory of B-Cell Neoplasia, Division of Experimental OncologyStrategic Research Program on CLLUniversità Vita Salute San Raffaele and IRCCS Ospedale San RaffaeleMilano, ItalyLink to full program:https://bit.ly/3OQ6634

Oncology Data Advisor
Updates in Mantle Cell Lymphoma

Oncology Data Advisor

Play Episode Listen Later Jul 20, 2022 56:43


Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Listen now! Click here to claim CME/NCPD/CPE credit: https://bit.ly/3cy6PrK

Seat Time : The Online Show for the Offroad Enthusiast
Reframing Your Mindset & Catching Up w/ Seat Time

Seat Time : The Online Show for the Offroad Enthusiast

Play Episode Play 53 sec Highlight Listen Later Jul 5, 2022 5:00


A left Rotator Cuff injury, a right MCL injury, a chainsaw to the left forearm and now a left fractured Scaphoid; it's been a rough 10 months. I can't let these injuries get me down though. I have to reframe my mindset to help myself recover as best as I can and also not push it too hard, too early.  Latest Seat Time Video: https://youtu.be/VHkp_1L8NxMSupport Seat TimeYoutube: https://bit.ly/3DBmyiKShop: http://bit.ly/SeatTimeShopInstagram: https://bit.ly/seattimeInstagramBuy a Coffee: https://bit.ly/2WCKuBoEnjoy #GettingSeattime during 2022, ride your bikes and tag @seattime in your adventures.Support the show (https://www.buymeacoffee.com/seattime)Support the show

SAGE Orthopaedics
AJSM July 2022 Podcast: A Biomechanical Comparison of the LaPrade Technique Versus a Novel Technique for Reconstruction of Medial-Sided Knee Injuries

SAGE Orthopaedics

Play Episode Listen Later Jul 5, 2022 21:41


Medial-sided knee injuries can lead to symptomatic valgus laxity or anteromedial rotatory instability and may require surgery, particularly in the setting of cruciate tears and tibial-sided medial collateral ligament (MCL) avulsions. The LaPrade (LP) technique utilizes 2 free grafts to reconstruct the superficial MCL (sMCL) and the posterior oblique ligament (POL). An alternative MCL reconstruction devised by the senior author comprises an anatomic single-bundle reconstruction using a free graft to reconstruct the sMCL with advancement and imbrication of the posteromedial capsule/POL (MCL anatomic reconstruction with capsular imbrication [MARCI] technique). These techniques have not been biomechanically compared with one another. In conclusion, although both techniques improved knee stability compared with destabilized conditions, the MARCI technique better approximated intact stability during valgus at knee flexion angles from 0° to 90° and external rotation loads at knee flexion angles ≤30° in a cadaveric model.   Click here to read the article.

The Manely Broncos Podcast
Manely Broncos: KJ Hamler's Road to Recovery, Why are People Sleeping on the Denver Broncos

The Manely Broncos Podcast

Play Episode Listen Later Jul 1, 2022 50:06


The Denver Broncos wide receiver room has been plagued with injuries in 2021. One player who seems to be coming along is KJ Hamler. Hamler spoke to the Broncos media about "His Why" in recovering from ACL, MCL and hip injury. It was a very candid and real sit down with Hamler. The guys recap that interview and talk about it. Lastly, if there are people sleeping on the Denver Broncos there has to be a reason. So what could possibly be those reasons? Tune in to find out.

CrossPolitic Studios
Daily News Brief for Friday, July 1st, 2022 [Daily News Brief]

CrossPolitic Studios

Play Episode Listen Later Jul 1, 2022 15:23


Happy Friday ladies and gentleman, and happy July 1st to you and yours’! I hope and pray y’all have an excellent weekend and Monday, celebrating our nations’ independence. Celebrate hard folks because our current administration hates that we have freedom… Before I get into the news: Club Membership Plug: Let’s stop and take a moment to talk about Fight Laugh Feast Club membership. By joining the Fight Laugh Feast Army, not only will you be aiding in our fight to take down secular & legacy media; but you’ll also get access to content placed in our Club Portal, such as past shows, all of our conference talks, and EXCLUSIVE content for club members that you won’t be able to find anywhere else. Lastly, you’ll also get discounts for our conferences… so if you’ve got $10 bucks a month to kick over our way, you can sign up now at flfnetwork.com https://thefederalist.com/2022/06/29/white-house-encourages-girls-15-or-younger-to-abort-without-their-parents-consent/ White House Encourages Girls ‘15 Or Younger’ To Abort Without Their Parents’ Consent The White House just promoted a website that guides girls under 15 to getting an abortion without their parents’ knowledge or consent. On June 25, the day after the Supreme Court overturned Roe v. Wade, the White House advertised an online Health and Human Services flier containing a link to AbortionFinder.org, a network that connects women wanting abortions to local facilities that will perform them and provides information on the legality of abortion in their state. The website has a search engine to find abortionists based on the seeker’s location and age, including for minors “15 or younger.” AbortionFinder.org also includes a link to the If/When/How Judicial Bypass (JB) Helpline, which is designed to help minors bypass their parents or guardians to obtain an abortion. This Judicial Bypass system cuts 14-16-year-olds off from their support systems, isolating them and allowing them to kill their children in utero and put their bodies through the trauma of abortion with no familial protection. There’s a picture in the article, and you can find the article in our show notes by the way… Despite studies showing that women who go through abortions suffer increased mental health issues than women who decide to give birth to their children, Biden and his administration are capitalizing on the outrage sparked by the overturning of Roe to target American youth. After the Dobbs decision, the Department of Health and Human Services immediately published a website, “ReproductiveRights.gov,” for the express purpose of providing “accurate and up-to-date information about access to and coverage of reproductive health care and resources.” This page — which is itself a misnomer since abortion is neither health care nor a right — though branding itself as full-range coverage of the choices available to women, made no reference at all to a woman’s choice to keep her baby and instead pandered almost entirely to abortion-related services. The website also linked to AbortionFinder.org, once again promoting the bypass of parental consent for minors to obtain abortions. https://thepostmillennial.com/breaking-supreme-court-rules-against-epas-authority-to-limit-emissions-by-remaking-energy-sector?utm_campaign=64487 Supreme Court rules against EPA's authority to limit emissions by remaking energy sector The Supreme Court on Thursday issued a ruling in the case of West Virginia v. Environmental Protection Agency. The 6-3 ruling sides with West Virginia, which sought to limit the Clean Air Act. At issue were the EPA's plans to use regulation to "reduce carbon pollution mostly by moving production to cleaner sources." Once the EPA determined this course of action, they began to limit allowable emissions from fossil fuel production. They enacted goals that they viewed as a "'reasonable' amount of shift which it based on modeling how much more electricity both natural gas and renewable sources could supply without causing undue cost increases or reducing the overall power supply." Chief Justice Roberts wrote in his opinion: "Since passage of the Act 50 years ago, EPA has exercised this authority by setting performance standards based on measures that would reduce pollution by causing plants to operate more cleanly. In 2015, however, EPA issued a new rule concluding that the 'best system of emission reduction' for existing coal-fired power plants included a requirement that such facilities reduce their own production of electricity, or subsidize increased generation by natural gas, wind, or solar sources." This meant that the EPA was effectively regulating coal businesses to wind down toward the end goal of no longer being in the business of providing energy. Roberts asked the question as to "whether this broader conception of EPA’s authority is within the power granted to it by the Clean Air Act." The opinion states that the EPA does not have this broad authority under the Clean Air Act, and that this power has not been bestowed by Congress. Hey, are you looking to make a move? Well you need to talk to our friends, Story Real Estate: Story Real Estate: Home. It’s where you build your legacy. Where traditions are started, seeds are planted, meals are shared, and stories are told. Home is where you prepare to go out into the world. Finding the home that’s perfect for your family is a big job. Story Real Estate is Moscow’s top real estate team. They give people real estate advice all over the country. Family homes, investments, land, new construction, or commercial— they know real estate. If you’ve thought about a move to Moscow or anywhere in the country, reach out to get connected with a Story Real Estate agent. Wherever you’re going, they can help guide you Home. Visit storyrealestate.com. https://www.washingtonexaminer.com/news/donald-trump-open-trump-desantis-gop-presidential-ticket Donald Trump is open to a ‘Trump, DeSantis’ 2024 presidential ticket Former President Donald Trump said his family is on board with the possibility of him running for president again in 2024. “Well, they love our country, and they hate to see what’s happening,” Trump said of former first lady Melania Trump and son Barron Trump. https://twitter.com/i/status/1542484310632046593 - Play Video DeSantis's popularity among registered Republican voters continues to climb. A recent poll showed about 45% would vote for Trump compared to 36% who leaned toward DeSantis, the closest any challenger has ever gotten to the former president in a GOP primary poll, with a difference of only 9 points. Now it’s time for the topic that I love… sports! We’ve got a fair bit to cover in the world of sports, so let’s get to it: https://www.outkick.com/australian-tennis-star-nick-kyrgios-spits-at-fan-in-wimbledon-calls-lineswoman-a-snitch/ Wimbledon is under way currently, and Australian tennis star Nick Kyrgios, has caught some attention: https://twitter.com/i/status/1541833358254243841 - Play Video Facing off against Britain’s Paul Jubb, the 27-year-old Kyrgios went through a gauntlet of emotion in the close win (6-3, 1-6, 5-7, 7-6 [3], 5-7). Kyrgios’ highlights on the day included calling a line judge a “snitch,” sending a tennis ball into orbit, requesting that a fan get escorted out of The Championships and spitting in the direction of the heckling fan after the match. The tennis star has long been known for his on-court antics and contentious persona. Kyrgios has received $113,000 in fines in ONE tournament, at the Southern Open in Cincinnati in the past. The more ya know… In other sports news, Kevin Durant has reportedly requested a trade from the Brooklyn Nets, this after his teammate and fellow star, Kyrie Irving, just signed an extension with the club. Whoops! The Phoenix Suns and Miami Heat are among the teams Durant has on his wish list for a potential trade, sources told Wojnarowski. However, the Nets are not tied to honoring any of Durant's preferred destinations and plan to make a deal that allows them the greatest return of assets, sources told Wojnarowski. There’s also rumor that Kyrie Irving wants to try and move with KD to his new team. Irving eventually opted into the final year of his contract after being unable to find a suitable sign-and-trade for the Nets to make from his preferred list of destinations -- one that included the Los Angeles Lakers, LA Clippers, New York Knicks, Heat, Dallas Mavericks and Philadelphia 76ers. Of those teams, however, only the Lakers were interested in giving Irving a max contract, sources told Wojnarowski -- and they didn't have any package to offer the Nets that was appealing enough to get a sign-and-trade deal done. Durant averaged 29.9 points, 7.4 rebounds and 6.4 assists this season, but he saw action in just 55 games during the regular season as he recovered from an MCL injury. And finally: USC, UCLA planning move from Pac-12 to Big Ten as early as 2024, sources say https://www.espn.com/college-sports/story/_/id/34173688/source-usc-ucla-considering-move-pac-12-big-ten USC and UCLA, two of the Pac-12's flagship programs, are planning to leave the conference for the Big Ten as early as 2024, and a move is considered imminent, sources confirmed to ESPN on Thursday. There is still a formal notification process, as the two schools have to let the Pac-12 know their intentions to leave. USC and UCLA also have to formally apply to the Big Ten. According to a source, that process is underway. Big Ten presidents and chancellors will meet to vote on the addition of USC & UCLA, sources told ESPN. Multiple sources told ESPN on Thursday that the move is expected to happen. A source called the next steps "formalities.” The reason this move would be less disruptive than potential moves in the ACC is that USC and UCLA have a grant of rights tied to the current Pac-12 television contract, which expires after the 2023 football season and 2023-24 school year. That's why the expectation is that both schools can go to the league for the 2024-25 season and not suffer any financial penalty. Pac-12 officials had been nudging both Los Angeles schools for years to extend the grant of rights. The fact that they didn't hinted that they had greater ambition. "We just got Sooner'd and Horn'd," a high-ranking university official at one of the Pac-12 schools told ESPN, referring to the decision made last year by Texas and Oklahoma to leave the Big 12 conference for the SEC. College sports has officially turned into a farm league for the NBA & NFL… That’s gunna do it for this CrossPolitic Daily News Brief. If you liked the show, hit that share button for me will ya? If you want to sign up for our conference, become a club member, or subscribe to our FLF Magazine, you can do all of that at flfnetwork.com. And as always, if you’d like to become a corporate partner with CrossPolitic, you should email me at garrison@fightlaughfeast.com. For CrossPolitic News, I’m Garrison Hardie. Have a great Fourth of July with you and yours, and Lord bless.

Daily News Brief
Daily News Brief for Friday, July 1st, 2022

Daily News Brief

Play Episode Listen Later Jul 1, 2022 15:23


Happy Friday ladies and gentleman, and happy July 1st to you and yours’! I hope and pray y’all have an excellent weekend and Monday, celebrating our nations’ independence. Celebrate hard folks because our current administration hates that we have freedom… Before I get into the news: Club Membership Plug: Let’s stop and take a moment to talk about Fight Laugh Feast Club membership. By joining the Fight Laugh Feast Army, not only will you be aiding in our fight to take down secular & legacy media; but you’ll also get access to content placed in our Club Portal, such as past shows, all of our conference talks, and EXCLUSIVE content for club members that you won’t be able to find anywhere else. Lastly, you’ll also get discounts for our conferences… so if you’ve got $10 bucks a month to kick over our way, you can sign up now at flfnetwork.com https://thefederalist.com/2022/06/29/white-house-encourages-girls-15-or-younger-to-abort-without-their-parents-consent/ White House Encourages Girls ‘15 Or Younger’ To Abort Without Their Parents’ Consent The White House just promoted a website that guides girls under 15 to getting an abortion without their parents’ knowledge or consent. On June 25, the day after the Supreme Court overturned Roe v. Wade, the White House advertised an online Health and Human Services flier containing a link to AbortionFinder.org, a network that connects women wanting abortions to local facilities that will perform them and provides information on the legality of abortion in their state. The website has a search engine to find abortionists based on the seeker’s location and age, including for minors “15 or younger.” AbortionFinder.org also includes a link to the If/When/How Judicial Bypass (JB) Helpline, which is designed to help minors bypass their parents or guardians to obtain an abortion. This Judicial Bypass system cuts 14-16-year-olds off from their support systems, isolating them and allowing them to kill their children in utero and put their bodies through the trauma of abortion with no familial protection. There’s a picture in the article, and you can find the article in our show notes by the way… Despite studies showing that women who go through abortions suffer increased mental health issues than women who decide to give birth to their children, Biden and his administration are capitalizing on the outrage sparked by the overturning of Roe to target American youth. After the Dobbs decision, the Department of Health and Human Services immediately published a website, “ReproductiveRights.gov,” for the express purpose of providing “accurate and up-to-date information about access to and coverage of reproductive health care and resources.” This page — which is itself a misnomer since abortion is neither health care nor a right — though branding itself as full-range coverage of the choices available to women, made no reference at all to a woman’s choice to keep her baby and instead pandered almost entirely to abortion-related services. The website also linked to AbortionFinder.org, once again promoting the bypass of parental consent for minors to obtain abortions. https://thepostmillennial.com/breaking-supreme-court-rules-against-epas-authority-to-limit-emissions-by-remaking-energy-sector?utm_campaign=64487 Supreme Court rules against EPA's authority to limit emissions by remaking energy sector The Supreme Court on Thursday issued a ruling in the case of West Virginia v. Environmental Protection Agency. The 6-3 ruling sides with West Virginia, which sought to limit the Clean Air Act. At issue were the EPA's plans to use regulation to "reduce carbon pollution mostly by moving production to cleaner sources." Once the EPA determined this course of action, they began to limit allowable emissions from fossil fuel production. They enacted goals that they viewed as a "'reasonable' amount of shift which it based on modeling how much more electricity both natural gas and renewable sources could supply without causing undue cost increases or reducing the overall power supply." Chief Justice Roberts wrote in his opinion: "Since passage of the Act 50 years ago, EPA has exercised this authority by setting performance standards based on measures that would reduce pollution by causing plants to operate more cleanly. In 2015, however, EPA issued a new rule concluding that the 'best system of emission reduction' for existing coal-fired power plants included a requirement that such facilities reduce their own production of electricity, or subsidize increased generation by natural gas, wind, or solar sources." This meant that the EPA was effectively regulating coal businesses to wind down toward the end goal of no longer being in the business of providing energy. Roberts asked the question as to "whether this broader conception of EPA’s authority is within the power granted to it by the Clean Air Act." The opinion states that the EPA does not have this broad authority under the Clean Air Act, and that this power has not been bestowed by Congress. Hey, are you looking to make a move? Well you need to talk to our friends, Story Real Estate: Story Real Estate: Home. It’s where you build your legacy. Where traditions are started, seeds are planted, meals are shared, and stories are told. Home is where you prepare to go out into the world. Finding the home that’s perfect for your family is a big job. Story Real Estate is Moscow’s top real estate team. They give people real estate advice all over the country. Family homes, investments, land, new construction, or commercial— they know real estate. If you’ve thought about a move to Moscow or anywhere in the country, reach out to get connected with a Story Real Estate agent. Wherever you’re going, they can help guide you Home. Visit storyrealestate.com. https://www.washingtonexaminer.com/news/donald-trump-open-trump-desantis-gop-presidential-ticket Donald Trump is open to a ‘Trump, DeSantis’ 2024 presidential ticket Former President Donald Trump said his family is on board with the possibility of him running for president again in 2024. “Well, they love our country, and they hate to see what’s happening,” Trump said of former first lady Melania Trump and son Barron Trump. https://twitter.com/i/status/1542484310632046593 - Play Video DeSantis's popularity among registered Republican voters continues to climb. A recent poll showed about 45% would vote for Trump compared to 36% who leaned toward DeSantis, the closest any challenger has ever gotten to the former president in a GOP primary poll, with a difference of only 9 points. Now it’s time for the topic that I love… sports! We’ve got a fair bit to cover in the world of sports, so let’s get to it: https://www.outkick.com/australian-tennis-star-nick-kyrgios-spits-at-fan-in-wimbledon-calls-lineswoman-a-snitch/ Wimbledon is under way currently, and Australian tennis star Nick Kyrgios, has caught some attention: https://twitter.com/i/status/1541833358254243841 - Play Video Facing off against Britain’s Paul Jubb, the 27-year-old Kyrgios went through a gauntlet of emotion in the close win (6-3, 1-6, 5-7, 7-6 [3], 5-7). Kyrgios’ highlights on the day included calling a line judge a “snitch,” sending a tennis ball into orbit, requesting that a fan get escorted out of The Championships and spitting in the direction of the heckling fan after the match. The tennis star has long been known for his on-court antics and contentious persona. Kyrgios has received $113,000 in fines in ONE tournament, at the Southern Open in Cincinnati in the past. The more ya know… In other sports news, Kevin Durant has reportedly requested a trade from the Brooklyn Nets, this after his teammate and fellow star, Kyrie Irving, just signed an extension with the club. Whoops! The Phoenix Suns and Miami Heat are among the teams Durant has on his wish list for a potential trade, sources told Wojnarowski. However, the Nets are not tied to honoring any of Durant's preferred destinations and plan to make a deal that allows them the greatest return of assets, sources told Wojnarowski. There’s also rumor that Kyrie Irving wants to try and move with KD to his new team. Irving eventually opted into the final year of his contract after being unable to find a suitable sign-and-trade for the Nets to make from his preferred list of destinations -- one that included the Los Angeles Lakers, LA Clippers, New York Knicks, Heat, Dallas Mavericks and Philadelphia 76ers. Of those teams, however, only the Lakers were interested in giving Irving a max contract, sources told Wojnarowski -- and they didn't have any package to offer the Nets that was appealing enough to get a sign-and-trade deal done. Durant averaged 29.9 points, 7.4 rebounds and 6.4 assists this season, but he saw action in just 55 games during the regular season as he recovered from an MCL injury. And finally: USC, UCLA planning move from Pac-12 to Big Ten as early as 2024, sources say https://www.espn.com/college-sports/story/_/id/34173688/source-usc-ucla-considering-move-pac-12-big-ten USC and UCLA, two of the Pac-12's flagship programs, are planning to leave the conference for the Big Ten as early as 2024, and a move is considered imminent, sources confirmed to ESPN on Thursday. There is still a formal notification process, as the two schools have to let the Pac-12 know their intentions to leave. USC and UCLA also have to formally apply to the Big Ten. According to a source, that process is underway. Big Ten presidents and chancellors will meet to vote on the addition of USC & UCLA, sources told ESPN. Multiple sources told ESPN on Thursday that the move is expected to happen. A source called the next steps "formalities.” The reason this move would be less disruptive than potential moves in the ACC is that USC and UCLA have a grant of rights tied to the current Pac-12 television contract, which expires after the 2023 football season and 2023-24 school year. That's why the expectation is that both schools can go to the league for the 2024-25 season and not suffer any financial penalty. Pac-12 officials had been nudging both Los Angeles schools for years to extend the grant of rights. The fact that they didn't hinted that they had greater ambition. "We just got Sooner'd and Horn'd," a high-ranking university official at one of the Pac-12 schools told ESPN, referring to the decision made last year by Texas and Oklahoma to leave the Big 12 conference for the SEC. College sports has officially turned into a farm league for the NBA & NFL… That’s gunna do it for this CrossPolitic Daily News Brief. If you liked the show, hit that share button for me will ya? If you want to sign up for our conference, become a club member, or subscribe to our FLF Magazine, you can do all of that at flfnetwork.com. And as always, if you’d like to become a corporate partner with CrossPolitic, you should email me at garrison@fightlaughfeast.com. For CrossPolitic News, I’m Garrison Hardie. Have a great Fourth of July with you and yours, and Lord bless.

Pod Awful
DADDY'S DAY 10: Juneteenth! w/ MINI MANSON & MCL - POD AWFUL PODCAST DF40

Pod Awful

Play Episode Listen Later Jun 21, 2022 117:05


HAPPY DADDY'S DAY! MINI MANSON, MCL, AND MY DAD ARE HERE! It's also JUNETEENTH, so in order to celebrate the day we finally remembered to free the slaves, I thought I would do the right thing and treat my own WHITE SLAVES a bit better. I give my dad a call to find out how to be a better daddy, and hear about the time he fought a child and lost. Then we catch up with MCL, the former pedorapper and current toilet slave. Finally, I thought I was bringing on Mini Manson for a fun time talking about his brother, David John Stewart's website, jesus-is-savior.com, but instead ALL HELL BREAKS LOOSE ONCE AGAIN. I guess I haven't been the best daddy to the Goons, so in order to make it up to Mini Manson, I help induct him into the FREEMASONS. Get the POD AWFTER SHOW where MCL digs in his butt and we call Mr. Burgers Sr. in the PIZZA FUND. Dregs Of Society Level: http://podawful.pizza  VIDEO: https://youtu.be/nuMn7vVn4vM RSS FEED: http://feeds.feedburner.com/podawful YOUTUBE: http://awful.tube DISCORD: http://podawful.com/discord TWITTER: http://podawful.com/twitter INSTAGRAM: http://podawful.com/instagram DLIVE: https://dlive.tv/PodAwful ODYSEE: https://odysee.com/@podawful:8 FACEBOOK: http://podawful.com/facebook CULT: http://podawful.com/cult MERCH: http://podawful.shop http://podawful.com #MiniManson #FathersDay #podawful Pod Awful Is an anti-podcast hosted by Jesse P-S

The Al Galdi Podcast
Episode 336: Ron Rivera speaks, Commanders players stand by Jack Del Rio and much more

The Al Galdi Podcast

Play Episode Listen Later Jun 15, 2022 64:59


10:19 - Commanders: in-depth react to Ron Rivera and various Commanders defensive players addressing the Jack Del Rio "dustup" controversy, including Ron changing his reasoning for fining Jack $100,000 31:28 - Commanders: analysis of Terry McLaurin no-showing the Commanders' mandatory minicamp, including comments from Ron Rivera, Daron Payne and Logan Thomas 43:17 - Commanders: will Logan Thomas be ready for Week 1 of the 2022 season off having suffered a torn ACL, MCL and meniscus in Week 13 of the 2021 season? 46:41 - Commanders: thoughts on Jamin Davis off comments from him about his bad rookie season and where he is at now 50:51 - Nationals: examining the reeling state of the Nats' pitching staff and more off a 10-4 loss to the Atlanta Braves 01:00:05 - Orioles: breakdown of a 6-5 win at the Toronto Blue Jays https://HelloFresh.com/Galdi16 and use the promo code Galdi16 Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Grit! with Chas Smith
170 - The Grit! June 11, 2022

The Grit! with Chas Smith

Play Episode Listen Later Jun 11, 2022 72:40 Very Popular


Florida Surf Film Fest co-founder Kevin Miller joins David and Chas to discuss the yin and yang of Gerry Lopez, the birth of the Endless Summer, how Kelly's 11 titles led to JJF's torn MCL, the creepy new surf cam causing backlash in Victoria, and they offer relationship advice as only three men with a combined seven marriages can. Plus Barrel or Nah?! Enjoy! Learn more about your ad choices. Visit megaphone.fm/adchoices

Stab Podcasts
The Truth About Wax + The Crosby Cola Interview

Stab Podcasts

Play Episode Listen Later Jun 10, 2022 83:38


The Drop is back to talk about everything that happened this week in surfing, fro El Salvador's $170M investment in the sport, who's in and who's out for Punta Roca, Italy's surprise pick for their assistant national surf coach, and a Surf Sin that everyone can relate to. As a special bonus, we've also got an interview with Crosby Colapinto talking about his new film by Stab and Monster, DNA: The Colapinto Brothers, which is now live on stabmag.com. Grab a warm glass of whole milk and settle in. Timecodes: - 3:30 El Salvador's $170M bet on surfing - 10:15 John's MCL injury - 17:00 Italy's new coach - 25:00 Surf Sin - 40:00 Crosby Colapinto interview